The CDMO/CMO market is experiencing significant growth, particularly in the Drug Substance A...
The CDMO/CMO market is experiencing significant growth, particularly in the Drug Substance A...
In Q4 2024, we partnered with an orthopedic medical device startup in the joint reconstructi...
The ChallengeA small molecule CDMO faced over a 70% turnover rate, struggled to meet product...
A cardiovascular medical device company (a publicly traded company generating around $300 mi...
Learn how Barrington James successfully assembled a dedicated commercial team for a mid-size...
A mid-sized medical device company, specializing in cardiovascular and hematology faced a re...
We delivered market insights and a VP Finance shortlist, supporting a Swiss oncology biotech...
Barrington James Board & Executive Partners are pleased to announce the appointment of&n...